CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
CRISPR Therapeutics reported Q1 2026 financial results featuring a strengthened balance sheet with $2.44 billion in cash, driven by $585.4 million in convertible note proceeds. Commercial momentum continued with CASGEVY generating $43 million in product revenue, as over 500 patients globally have initiated treatment. Pipeline advancement included FDA IND clearance for zugo-cel in autoimmune neurologic diseases and the progression of multiple in vivo liver programs. The company expects to initiate clinical trials for CTX340 (hypertension) in the first half of 2026 and CTX460 (AATD) by mid-2026.
Key figures
- Drug Name
- CASGEVY
- Net loss usd
- 122900000
- Rnd expenses usd
- 68600000
- Casgevy product revenue
- 43000000
- Convertible notes proceeds usd
- 585400000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.